(FM) Oncología
Departamento académico
![Foto de (FM) Oncología](/img/uploaded/1575D5546D141A10EB89AE669C8B8533.jpg)
![Foto de University of Manchester](/img/noimage_org.png)
University of Manchester
Mánchester, Reino UnidoPublicaciones en colaboración con investigadores/as de University of Manchester (13)
2022
-
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Nature Cancer, Vol. 3, Núm. 6, pp. 696-709
-
Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry
Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121
2021
-
Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial
ESMO Open, Vol. 6, Núm. 2
-
Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)
British Journal of Cancer
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
2020
-
Current and novel therapeutic opportunities for systemic therapy in biliary cancer
British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059
-
Epigenetic EGFR gene repression confers sensitivity to therapeutic BRAFV600E blockade in colon neuroendocrine carcinomas
Clinical Cancer Research, Vol. 26, Núm. 4, pp. 902-909
2019
-
Clinical presentation, diagnosis and staging of cholangiocarcinoma
Liver International, Vol. 39, Núm. S1, pp. 98-107
2017
-
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience
Future Oncology, Vol. 13, Núm. 7, pp. 615-624
-
PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
Cell Reports, Vol. 20, Núm. 8, pp. 1818-1829
-
Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM)
Annals of Translational Medicine, Vol. 5, Núm. 19
2016
-
Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): A randomised, double-blind, placebo-controlled phase 3 trial
The Lancet, Vol. 387, Núm. 10023, pp. 1066-1074